Five trials (Pitt et al., 2013; Bakris et al., 2015; Katayama et al., 2017; Bakris et al., 2020; Pitt et al., 2021) compared the urinary albumin-to-creatinine ratio (UACR) of finerenone (n = 6,732) versus placebo (n = 6,364) groups of CKD patients. Here, ALB is linked to chronic kidney disease.